我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

热毒宁治疗儿童社区获得性肺炎的随机对照双盲试验研究(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2015年04期
页码:
73-77
栏目:
临床研究
出版日期:
2015-07-25

文章信息/Info

Title:
Effect of Reduning Injection on Duration of Hospitalization in Chinese ChildrenPresenting with Acute Pneumonia
作者:
陈勇蒋宇桐杨慧敏
成都市龙泉驿区妇幼保健院儿科,四川 成都 610100
Author(s):
CHEN Yong JIANG Yutong YANG Huimin
Department of Pediatrics, Child Health Hospital of Chengdu Longquan District, Chengdu 610100, China
关键词:
儿童 肺炎 热毒宁 中药 注射剂 疗效
Keywords:
children pneumonia Reduning traditional Chinese medicine injection efficacy
分类号:
R272.5
DOI:
-
文献标识码:
A
摘要:
目的热毒宁注射液(Reduning injection,RI)对于低龄儿童的社区获得性肺炎(Community-Acquired Pneumonia,CAP)的疗效仍不清楚,本研究拟观察RI对住院CAP患儿的疗效。方法采用随机,双盲,安慰剂对照的试验方法,共纳入1198例患儿(年龄12~36个月),治疗组采用5 mL的RI,安慰组采用5 mL生理盐水,分别加入100 mL生理盐水静脉滴注,每天1次,7 d 1疗程。结果与安慰组相比,RI治疗组能显著缩短患儿的总住院时间(P<0.001),同时显著降低住院后重症脓毒症的发生率(P=0.02)。另外,RI能改善临床症状,显著减少呼吸急促(P=0.001)和持续发热时间(P=0.000)。结论本试验结果提示中药注射液RI可用于低龄儿童CAP的治疗,其能显著改善住院CAP患儿的总住院时间、降低并发症,改善患儿的临床治疗结果。
Abstract:
Objective Reduning injection(Reduning injection, RI) to treat children with pneumonia, but the specific treatment for children with community-acquired pneumonia(Community-acquired pneumonia, CAP) remains unclear. Methods This study used a randomized, double-blind, placebo-controlled Reduning Injection clinical trials, patients treated with antibiotics after hospital auxiliary imaging confirmed community-acquired pneumonia(age 12-36 months). Trial group using 5 mL of normal saline RI adding 100 mL intravenous infusion once daily for 7 days. Using 100 mL of normal saline placebo intravenously add 5 mL of normal saline for intravenous infusion. Drip rate of 10-15 drops per min, once per day. Results The study included 1198 cases of children. RI during hospitalization can significantly shorten the overall length of hospital stay in children(P<0.001). In addition, Reduning group can significantly reduce the incidence of severe sepsis hospitalization(P=0.02), while it able to improve the clinical symptoms, significantly reduced breathlessness(P=0.001) and reduced the duration of fever(P=0.000). Conclusion This randomized clinical trial for the treatment of CAP application RI children to provide evidence of the positive evidence supporting the beneficial of Reduning Injection for children with acute pneumonia.

参考文献/References

[1] Queen MA, Myers AL, Hall M, et al. Comparative effectiveness of empiric antibiotics for community-acquired pneumonia[J]. Pediatrics,2014,133(1):e23-29.
[2] Fischer JE, Steiner F, Zucol F, et al. Use of simple heuristics to target macrolide prescription in children with community-acquired pneumonia[J]. Arch Pediatr Adolesc Med,2002,156(10):1005-1008.
[3] Dirlewanger M, Krahenbuhl JD, Fanconi S, et al. Community-acquired pneumonia in children aged 2 months to 5 years:application of the WHO guidelines in a developed country setting(Switzerland)[J]. Eur J Pediatr,2002,161(8):460-461.
[4] Garau J, Baquero F, Perez-Trallero E, et al. Factors impacting on length of stay and mortality of community-acquired pneumonia[J]. Clin Microbiol Infect,2008,14(4):322-329.
[5] Zhang Q, Guo Z, Bai Z, et al. A 4 year prospective study to determine risk factors for severe community acquired pneumonia in children in southern China[J]. Pediatr Pulmonol,2013,48(4):390-397.
[6] Wrotek A, Pawlik K, Jackowska T. Soluble receptor for urokinase plasminogen activator in community-acquired pneumonia in children[J]. Adv Exp Med Biol,2013,788:329-334.
[7] Nascimento-Carvalho CM, Oliveira JR, Cardoso MR, et al. Respiratory viral infections among children with community-acquired pneumonia and pleural effusion[J]. Scand J Infect Dis,2013,45(6):478-483.
[8] Barsam FJ, Borges GS, Severino AB, et al. Factors associated with community-acquired pneumonia in hospitalised children and adolescents aged 6 months to 13 years old[J]. Eur J Pediatr,2013,172(4):493-499.
[9] Sicot N, Khanafer N, Meyssonnier V, et al. Methicillin resistance is not a predictor of severity in community-acquired Staphylococcus aureus necrotizing pneumonia-results of a prospective observational study[J]. Clin Microbiol Infect,2013,19(3):e142-148.
[10] Williams DJ, Shah SS, Myers A, et al. Identifying pediatric community-acquired pneumonia hospitalizations:Accuracy of administrative billing codes[J]. JAMA Pediatr,2013,167(9):851-858.
[11] Wang XF, Liu JP, Shen KL, et al. A cross-sectional study of the clinical characteristics of hospitalized children with community-acquired pneumonia in eight eastern cities in China[J]. BMC Complement Altern Med,2013,13:367.
[12] Wang LJ, Mu SC, Lin CH, et al. Fatal community-acquired pneumonia:18 years in a medical center[J]. Pediatr Neonatol,2013,54(1):22-27.
[13] Tuerlinckx D, Smet J, De Schutter I, et al. Evaluation of a WHO-validated serotype-specific serological assay for the diagnosis of pneumococcal etiology in children with community-acquired pneumonia[J]. Pediatr Infect Dis J,2013,32(7):e277-284.
[14] Schauner S, Erickson C, Fadare K, et al. Community-acquired pneumonia in children:a look at the IDSA guidelines[J]. J Fam Pract,2013,62(1):9-15.
[15] Patria F, Longhi B, Tagliabue C, et al. Clinical profile of recurrent community-acquired pneumonia in children[J]. BMC Pulm Med,2013,13:60.
[16] Lu G, Li J, Xie Z, et al. Human metapneumovirus associated with community-acquired pneumonia in children in Beijing, China[J]. J Med Virol,2013,85(1):138-143.
[17] Nagy B, Gaspar I, Papp A, et al. Efficacy of methylprednisolone in children with severe community acquired pneumonia[J]. Pediatr Pulmonol,2013,48(2):168-175.
[18] Myers AL, Hall M, Williams DJ, et al. Prevalence of bacteremia in hospitalized pediatric patients with community-acquired pneumonia[J]. Pediatr Infect Dis J,2013,32(7):736-740.
[19] Du JM, Sang G, Jiang CM, et al. Relationship between plasma copeptin levels and complications of community-acquired pneumonia in preschool children[J]. Peptides,2013,45:61-65.
[20] 冯旰珠,周锋,黄茂,等. 热毒宁抗呼吸道合胞病毒(RSV,Long株)作用体外实验研究[J]. 南京医科大学学报(自然科学版),2007,27(9):1009-1012.
[21] 黄小民,柳于介,何煜舟,等. 热毒宁注射液治疗急性上呼吸道感染的临床研究[J]. 中国临床药理学与治疗学,2006,11(4):470-473.
[22] 冯旰珠,周锋,黄茂,等. 热毒宁注射液对人鼻病毒(N36)的体外抑制作用[J]. 中国药科大学学报,2008,39(3):262-266.
[23] 冯旰珠,周锋,黄茂,等. 热毒宁注射液对腺病毒-3的体外抑制作用[J]. 中国新药与临床杂志,2007,26(8):573-577.
[24] 张新庄,萧伟,徐筱杰,等. 利用网络药理学方法研究热毒宁注射液抗流感病毒的分子作用机制[J]. 物理化学学报,2013,29(7):1415-1420.
[25] 周卫芳,季伟. 热毒宁治疗儿童急性呼吸道感染伴发热的疗效观察[J]. 中国妇幼保健,2006,21(21):3037-3038.
[26] Mandell LA,Wunderink RG,Anzueto A,et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults[J]. Clin Infect Dis,2007,44(S2):S27-72.

备注/Memo

备注/Memo:
收稿日期: 2015 - 01 - 08 作者简介: 陈勇(1971-),男,四川通江人,副主任医师,主要从事儿科呼吸及新生儿疾病的临床诊治。
更新日期/Last Update: 2015-07-30